Navigation Links
Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
Date:9/15/2008

CAMBRIDGE, Mass., Sept. 15 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that it has met its second milestone in its option agreement with the Novartis Option Fund and will move on to the next phase to validate targets for inflammatory bowel disease (IBD) using Cequent's proprietary TransKingdom RNA interference [tkRNAi(TM)] technology in animal models. Specific payment terms and targets were not disclosed.

"IBD is actually a spectrum of diseases, and the power of RNAi is that you could potentially design therapeutics specifically to target the individual forms of the disease," said Cequent President and CEO, Peter Parker. "When we started the Novartis program, we were evaluating eight targets simultaneously as potential therapeutics for inflammatory bowel disease. Our milestone goal, which we accomplished, was to winnow the targets down to three that we will further validate in in vivo animal trials before Cequent selects the single target to be the subject of the Option agreement. We believe our success with this work, along with progress in our other development programs for Familial Polyposis (FAP) and Human Papilloma Virus (HPV), demonstrate the potential of our tkRNAi technology to become an important tool to better understand, and ultimately, to treat many devastating diseases."

Said Steven Tregay, PhD, a managing director of Novartis Option Fund, "We are impressed with both the quality and speed of the work that Cequent is doing on the IBD program -- as well as the potential of their tkRNAi platform. Creating compounds to address eight targets and completing in vitro screening in only nine months would have been virtually impossible with traditional small-molecule-based drug discovery technologies. We're pleased to release the milestone payment to Cequent, and look forward to our continued relationship both as venture investor and partner."

About Cequent Pharmaceuticals, Inc. (http://www.cequentpharma.com)

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases -- from inflammatory diseases to cancer -- based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at The Pasteur Institute (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006.

About Novartis Option Fund (http://www.venturefund.novartis.com)

The Novartis Option Fund is a $200 million fund that is part of the Novartis Corporate Venture Funds. Established in 1996, the Novartis Venture Funds currently manage over $550 million in committed capital and is invested in more than 50 private companies. The objective of the Novartis Option Fund is to seed innovative companies through initial and follow-on investment. The initial investment is coupled with an option to a specific therapeutic program providing early validation for the start-up company's technology/programs by large pharma. The Novartis Venture Funds team of nine investment professionals located in Basel, Switzerland and Cambridge, Massachusetts, brings together extensive expertise in the biotech and pharmaceutical industry and venture capital.


'/>"/>
SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
2. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
3. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
4. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
5. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
6. VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
7. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
8. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
9. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
10. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
11. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... TEL AVIV, Israel , May 24, 2016   ... on providing physicians with artificial intelligence, real-time decision support tools ... selected to present at the 2016 Israeli Advanced Technology Industries ... part of Israel,s 15th National Life ... to 26th at the David Intercontinental Hotel in ...
(Date:5/23/2016)... ... ... blood donations in South Texas and across the nation is growing. , But according to ... are on the decline. In fact, donations across the country are at their lowest point ... the last four years alone. , There is no substitute for blood. , “We want ...
(Date:5/23/2016)... , May 23, 2016 Oxitec CEO ... th at 10:15 a.m. ET before the United States ... genetically engineered mosquitos can play in controlling the spread of ... the Zika virus.      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ... mosquito with a self-limiting gene. Trials in Brazil ...
(Date:5/23/2016)... ... May 23, 2016 , ... Foresight Institute ... announced the winners for the 2015 Foresight Institute Feynman Prizes. , These ... two categories, one for experiment and the other for theory in nanotechnology. Prof. ...
Breaking Biology Technology:
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
Breaking Biology News(10 mins):